Alzheimer’s Disease Therapy

Advances in Alzheimer Disease Therapy

InhaltsangabeI. Pathological Basis of Therapy in Alzheimer’s Disease.- Criteria for the Diagnosis of Alzheimer’s Disease.- Criteria for the Clinical Diagnosis of Alzheimer’s Disease: Transcultural Aspects.- Clinical And Neuropathological Findings from Cerad.- Differentiating Alzheimer Disease and Vascular Dementia: Reframing the Question.- Neuropathology Of Alzheimer’s Disease.- Basis of Structural Alzheimer Disease and Some Pathogenic Concepts.- Regional Distribution of Neuropathological Changes in Alzheimer’s Disease.- Alzheimer Neurofibrillary Degeneration: A Feasible and Key Target for Therapeutics.- Diabetes and Dementia: A Retrospective Neuropathologic Study of Old Diabetics Compared to Non-Diabetic Controls.- Processing of Amyloid, Cytoskeletal Damage and Apolipoproteins.- Isoform-Specific Metabolism of Apolipoprotein E: Implications for Alzheimer’s Disease.- Apolipoprotein E4 and Cholinergic Activity in Alzheimer’s Disease.- A New Focus on Cytoskeletal Therapy in Alzheimer’s Disease.- Novel Cathepsin D Inhibitors Prevent the ?-Secretase-Derived Intracellular Formation of a 12 kDA Potentially Amyloidogenic Product in Human Cells.- Cellular and Test Tube Models of Amyloid-? Formation.- Effects of ?-Amyloid (1-40) Peptide Injection in the Nucleus Basalis.- ?Amyloid Precursor Protein – Role in Cognitive Brain Function?.- Peptides Inhibitor of Amyloidogenesis in Alzheimer’s Disease.- Cell Death: Excitotoxins, Apoptosis And Hypometabolism.- Apoptosis and Alzheimer’s Disease: A Self-Assembly and the Initiation of Apoptosis by Plasma Membrane Receptor Cross-Linking.- NMDA Receptor Dysfunction in Alzheimer’s Disease.- Role of Neuron-Glia Interactions in Brain Energy Metabolism: Implications for Neurodegenerative Disorders.- Neurotrophins, Growth Factors and Neuroprotectors.- Neurotrophins, Growth Factors and Mimetic Agents as Neuroprotectors in the Treatment of Alzheimer’s Disease.- Cortical Synaptogenesis and Behavioural Consequences in CNS Lesioned Animals Receiving Neurotrophic Factor Therapy.- Animal Models.- APP Knockout and APP Over-Expression in Transgenic Mice.- Alpha2c-Adrenoceptor Overexpressing Mice as a Model to Study Cognitive Functions of Alpha2-Adrenoceptors.- ?-APP-751 Transgenic Mice: Deficits In Learning And Memory.- II. The Cholinergic System in Brain.- Treatment of Alzheimer Disease.- Central and Peripheral Consequences of Cholinergic Imbalance in Alzheimer’s Disease.- The Anatomy of Monoaminergic-Cholinergic Interactions in the Primate Basal Forebrain.- Pharmacological Induction of Cholinergic Hypofunction as a Tool for Evaluating Cholinergic Therapies.- Rational Design of New Acetylcholinesterase Inhibitors.- Advances in Understanding Cholinergic Brain Neurons: Implications in the Use of Citicoline (CDP Choline) to Treat Stroke.- Cholinesterase Inhibitors in Alzheimer Disease Treatment.- Cholinesterase Inhibitors Do More than Inhibit Cholinesterase.- Long-Term Tacrine Treatment: Effect on Nursing Home Placement and Mortality.- Cholinesterase Inhibitors: An Overview of Their Mechanisms of Action.- Preclinical Pharmacology of Metrifonate: A Promise for Alzheimer Therapy.- Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer’s Disease.- Phenserine: A Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and ?-APP Processing.- An Overview of the Development of SDZ ENA 713: A Brain Selective Cholinesterase Inhibitor.- Preclinical and Clinical Progress with Huperzine A: A Novel Acetylcholinesterase Inhibitor.- P11467: An Orally-Active Acetylcholinesterase Inhibitor and ?2-Adrenoceptor Antagonist for Alzheimer’s Disease.- Cholinesterase Inhibitors as Therapy in Alzheimer’s Disease: Benefit to Risk Considerations in Clinical Application.- III. Nicotinic and Muscarinic Cholinergic Agonists.- Nicotinic Agonists.- Molecular Histochemistry of Nicotinic Receptors in Human Brain.- The Nicotinic Cholinergic System and ?-Amyloidosis.- RJR-2403: A CNS-Selective Nicotinic Agonist with